Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G S Germain

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Molecular Pharmacology|January 13, 1998
Characterization of a novel bisacridone and comparison with PSC 833 as a potent and poorly reversible modulator of P-glycoproteinJ K Horton, K N Thimmaiah, G A Altenberg, et al.
Cancer Research|February 24, 1999
Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cellsH Hosoi, M B Dilling, T Shikata, et al.
Cancer Chemotherapy and Pharmacology|January 27, 2000
The influence of recombinant human insulin-like growth factor-I (rhIGF-I) on cell growth and cytotoxicity of drugs in childhood rhabdomyosarcoma cell lines and xenograft modelsC E Gidding, G S Germain, M B Dilling, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Molecular Pharmacology|January 13, 1998
Characterization of a novel bisacridone and comparison with PSC 833 as a potent and poorly reversible modulator of P-glycoproteinJ K Horton, K N Thimmaiah, G A Altenberg, et al.
Cancer Research|February 24, 1999
Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cellsH Hosoi, M B Dilling, T Shikata, et al.
Cancer Chemotherapy and Pharmacology|January 27, 2000
The influence of recombinant human insulin-like growth factor-I (rhIGF-I) on cell growth and cytotoxicity of drugs in childhood rhabdomyosarcoma cell lines and xenograft modelsC E Gidding, G S Germain, M B Dilling, et al.
Pageof 2